IL273578B2 - Antibodies directed against PD-1 and methods of use thereof - Google Patents

Antibodies directed against PD-1 and methods of use thereof

Info

Publication number
IL273578B2
IL273578B2 IL273578A IL27357820A IL273578B2 IL 273578 B2 IL273578 B2 IL 273578B2 IL 273578 A IL273578 A IL 273578A IL 27357820 A IL27357820 A IL 27357820A IL 273578 B2 IL273578 B2 IL 273578B2
Authority
IL
Israel
Prior art keywords
seq
antibody
pdl1
amino acid
binding
Prior art date
Application number
IL273578A
Other languages
English (en)
Hebrew (he)
Other versions
IL273578B1 (en
IL273578A (en
Inventor
Gunde Tea
Brock Matthias
Hess Christian
Simonin Alexandre
Original Assignee
Numab Therapeutics AG
Gunde Tea
Brock Matthias
Hess Christian
Simonin Alexandre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195781.4A external-priority patent/EP3470429A1/en
Application filed by Numab Therapeutics AG, Gunde Tea, Brock Matthias, Hess Christian, Simonin Alexandre filed Critical Numab Therapeutics AG
Publication of IL273578A publication Critical patent/IL273578A/en
Publication of IL273578B1 publication Critical patent/IL273578B1/en
Publication of IL273578B2 publication Critical patent/IL273578B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Liquid Crystal Substances (AREA)
IL273578A 2017-10-10 2018-10-09 Antibodies directed against PD-1 and methods of use thereof IL273578B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17195781.4A EP3470429A1 (en) 2017-10-10 2017-10-10 Antibodies targeting pdl1 and methods of use thereof
EP18167094 2018-04-12
EP18180816 2018-06-29
PCT/EP2018/077511 WO2019072869A1 (en) 2017-10-10 2018-10-09 PDL1 TARGETING ANTIBODIES AND METHODS OF USE THEREOF

Publications (3)

Publication Number Publication Date
IL273578A IL273578A (en) 2020-05-31
IL273578B1 IL273578B1 (en) 2025-11-01
IL273578B2 true IL273578B2 (en) 2026-03-01

Family

ID=63834022

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273578A IL273578B2 (en) 2017-10-10 2018-10-09 Antibodies directed against PD-1 and methods of use thereof
IL323510A IL323510A (en) 2017-10-10 2025-09-21 Antibodies directed against 1PDL and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL323510A IL323510A (en) 2017-10-10 2025-09-21 Antibodies directed against 1PDL and methods of use thereof

Country Status (11)

Country Link
US (2) US12077588B2 (enExample)
EP (1) EP3694879A1 (enExample)
JP (3) JP7791650B2 (enExample)
KR (2) KR20200063147A (enExample)
CN (2) CN120248120A (enExample)
AU (2) AU2018348430B2 (enExample)
CA (1) CA3074802A1 (enExample)
IL (2) IL273578B2 (enExample)
MA (1) MA50353A (enExample)
SG (1) SG11202001654TA (enExample)
WO (1) WO2019072869A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110709418B (zh) * 2017-06-05 2023-09-26 努玛治疗有限公司 新型抗hsa抗体
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
SG11202103000WA (en) * 2019-04-26 2021-04-29 I Mab Biopharma Us Ltd Human pd-l1 antibodies
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
PE20260551A1 (es) * 2023-05-19 2026-03-04 Numab Therapeutics AG Dominios variables de anticuerpos y anticuerpos con inmunogenicidad disminuida
IL328540A (en) 2023-12-22 2026-07-01 Numab Therapeutics AG Antibody binding complexes specific for LILRB2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2017118321A1 (en) * 2016-01-04 2017-07-13 Harbour Biomed Limited Anti-pd-l1 antibodies and uses thereof
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
ES2367430T3 (es) * 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2911946A1 (en) * 2013-05-10 2014-11-13 Numab Ag Bispecific constructs and their use in the treatment of various diseases
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
KR20250091329A (ko) 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷
KR102317479B1 (ko) * 2017-05-05 2021-10-26 노키아 테크놀로지스 오와이 무선 링크 제어 상태 보고

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2017118321A1 (en) * 2016-01-04 2017-07-13 Harbour Biomed Limited Anti-pd-l1 antibodies and uses thereof
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins

Also Published As

Publication number Publication date
JP7791650B2 (ja) 2025-12-24
JP2023166403A (ja) 2023-11-21
CN120248120A (zh) 2025-07-04
IL273578B1 (en) 2025-11-01
KR20200063147A (ko) 2020-06-04
JP2021501569A (ja) 2021-01-21
IL323510A (en) 2025-11-01
US20250066482A1 (en) 2025-02-27
JP7874215B2 (ja) 2026-06-15
CN111225926A (zh) 2020-06-02
US12077588B2 (en) 2024-09-03
CA3074802A1 (en) 2019-04-18
JP7649825B2 (ja) 2025-03-21
EP3694879A1 (en) 2020-08-19
KR20250057935A (ko) 2025-04-29
IL273578A (en) 2020-05-31
AU2025271488A1 (en) 2026-01-08
US20200283528A1 (en) 2020-09-10
WO2019072869A1 (en) 2019-04-18
AU2018348430A1 (en) 2020-03-12
SG11202001654TA (en) 2020-03-30
MA50353A (fr) 2020-08-19
AU2018348430B2 (en) 2025-09-04
JP2025102791A (ja) 2025-07-08
CN111225926B (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
IL265800A (en) Anti-lag-3 antibodies and methods of using them
PT3618863T (pt) Anticorpos anti-tigit e seus métodos de utilização
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
IL259495A (en) Antibodies and methods for using them
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
IL265957A (en) Anti-c1s antibodies and methods of using them
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
IL273841A (en) Antibodies directed against cd137 and methods of their use
SG11201803567XA (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL255336A0 (en) Chimeric antigen receptors and methods of using them
IL270793A (en) Anti-HTRA1 antibodies and methods of using them
IL273578A (en) Antibodies directed against 1PDL and methods of use thereof
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
IL268568A (en) TRAILshort antibody and methods of use
ZA202002144B (en) Antibodies and methods of use
HK40031482A (en) Antibodies targeting pdl1 and methods of use thereof